Eclipse buy gives Bionomics cancer stem cell foothold
This article was originally published in Scrip
The Australian drug development firm Bionomics is spending Aus$10 million ($10.5 million) to acquire a private US venture that will give it both candidate antibody therapeutics against cancer stem cells (CSCs) and a direct presence in the US.
You may also be interested in...
Lim, CEO of Ignyta when it was sold to Roche earlier this year, has moved on to the start-up Erasca with $42m in Series A venture cash to develop "precision oncology" drugs.
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.